Open an account

Bio-Rad Laboratories

BIO.B · NYSE

$379.50+$15.35 (+4.22%)TodayMarket closed ·
No price history for this range.

About BIO.B

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. The company is headquartered in Hercules, California and currently employs 7,450 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Employees
7,450
Headquarters
Hercules, California
Listed
Mar 17, 1980
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
bio-rad.com

BIO.B key statistics

Market cap
10.22B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
11
Volume
232
Open price
$380.57
High today
$379.50
Low today
$379.50
52 Week high
$365.08
52 Week low
$244.54

Bio-Rad Laboratories (BIO.B) at a glance

As of Oct 27, 2026, Bio-Rad Laboratories (BIO.B) shares are priced at $379.50, giving the company a market cap of 10.22B and a price-to-earnings ratio of 0.00.

Volume so far is 232 shares, above the average of 11 shares a day.

Over the past year Bio-Rad Laboratories has ranged from $244.54 to $365.08, and now sits 112% of the way up that range.

Bio-Rad Laboratories met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $2.62 per share against an estimate of $1.77.

The average analyst price target is $373.49, 1.6% below the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

20%of 5 analyst ratings say Buy
  • Buy20.0%
  • Hold80.0%
  • Sell0.0%
Price target · 6 analystsAvg $373.49
Low
$341.78
Now
$379.50
High
$413.65

BIO.B earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 37.4% on average.

  1. Q3 FY24: reported $2.01 per share against an estimate of $1.17
  2. Q4 FY24: reported $2.90 per share against an estimate of $2.90
  3. Q1 FY25: reported $2.54 per share against an estimate of $1.83
  4. Q2 FY25: reported $2.61 per share against an estimate of $1.75
  5. Q3 FY25: reported $2.26 per share against an estimate of $1.95
  6. Q4 FY25: reported $2.51 per share against an estimate of $2.73
  7. Q1 FY26: reported $1.89 per share against an estimate of $2.00
  8. Q2 FY26: reported $2.62 per share against an estimate of $1.77

BIO.B news

  • Press releaseBusiness Wire

    Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026

  • Press releaseBusiness Wire

    Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum

  • Press releaseBusiness Wire

    Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference

  • Press releaseBusiness Wire

    Bio-Rad Reports Second-Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026

Similar companies

Companies in the same industry as Bio-Rad Laboratories

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.